Vertex Pharmaceuticals Incorporated (VRTX)

168.16
NASDAQ
Prev Close 168.16
Day Low/High 0.00 / 0.00
52 Wk Low/High 144.07 / 195.81
Exchange NASDAQ
Shares Outstanding 255.66B
Market Cap 42.99B
Div & Yield N.A. (N.A)
Cramer: Trump Doesn't Deserve All the Credit for Stock Rally

Cramer: Trump Doesn't Deserve All the Credit for Stock Rally

Of stocks seeing the biggest gains since the presidential election, only a few owe their success to Trump.

Vertex Announces Presentations Of Data At North American Cystic Fibrosis Conference That Demonstrate Important Progress Toward Goal Of Helping All People With CF

Vertex Announces Presentations Of Data At North American Cystic Fibrosis Conference That Demonstrate Important Progress Toward Goal Of Helping All People With CF

Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced presentations of data at the Annual North American Cystic Fibrosis Conference (NACFC), November 2 to 4, 2017, in Indianapolis, from across the...

Phase 3 Studies Of The Tezacaftor/Ivacaftor Combination Treatment In People With Cystic Fibrosis Ages 12 And Older Published In The New England Journal Of Medicine

Phase 3 Studies Of The Tezacaftor/Ivacaftor Combination Treatment In People With Cystic Fibrosis Ages 12 And Older Published In The New England Journal Of Medicine

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the New England Journal of Medicine (NEJM) published two articles with results from two Phase 3 studies of the tezacaftor/ivacaftor...

Vertex To Present At The Credit Suisse Healthcare Conference On November 7

Vertex To Present At The Credit Suisse Healthcare Conference On November 7

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Credit Suisse Healthcare Conference on Tuesday, November 7, 2017 at 10:35 a.

Vertex Announces New $750,000 Program To Support The Work Of The Next Generation Of Cystic Fibrosis Researchers

Vertex Announces New $750,000 Program To Support The Work Of The Next Generation Of Cystic Fibrosis Researchers

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today a new $750,000 program to support the work of young faculty who are newly establishing independent research programs in cystic fibrosis (CF).

Vertex Reports Third-Quarter 2017 Financial Results

Vertex Reports Third-Quarter 2017 Financial Results

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2017.

Vertex Doubles Scholarship Program To Support The Academic And Professional Advancement Of People Living With Cystic Fibrosis And Their Families

Vertex Doubles Scholarship Program To Support The Academic And Professional Advancement Of People Living With Cystic Fibrosis And Their Families

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) has doubled the number of scholarships for people living with cystic fibrosis (CF) and their immediate family members.

Vertex Announces 10-Year, $500 Million Corporate Giving Commitment

Vertex Announces 10-Year, $500 Million Corporate Giving Commitment

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced a 10-year, $500 million corporate giving commitment focused on providing patient and caregiver support including access to our medicines; expanding our...

Vertex To Announce Third Quarter 2017 Financial Results On October 25

Vertex To Announce Third Quarter 2017 Financial Results On October 25

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2017 financial results on Wednesday, October 25, 2017 after the financial markets close.

Vertex To Present At The Leerink Partners Roundtable Series On September 27

Vertex To Present At The Leerink Partners Roundtable Series On September 27

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology on Wednesday, September 27, 2017 at 11:30 a.

Vertex Announces Upcoming Presentations Of Data At 2017 North American Cystic Fibrosis Conference

Vertex Announces Upcoming Presentations Of Data At 2017 North American Cystic Fibrosis Conference

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that 11 abstracts from its cystic fibrosis (CF) research and development program will be presented at the annual North American Cystic Fibrosis...

Vertex To Present At The Morgan Stanley Healthcare Conference On September 11

Vertex To Present At The Morgan Stanley Healthcare Conference On September 11

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Morgan Stanley Healthcare Conference on Monday, September 11, 2017 at 1:40 p.

Vertex Pharmaceuticals Could Be Headed Higher Once Again

Vertex Pharmaceuticals Could Be Headed Higher Once Again

Trade from the long side, but have a sell stop below $149 in case of a reversal.

Vertex Appoints Tom Graney As Senior Vice President And Chief Financial Officer

Vertex Appoints Tom Graney As Senior Vice President And Chief Financial Officer

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the appointment of Tom Graney to the role of Senior Vice President and Chief Financial Officer (CFO).

Vertex Announces Acceptance Of Its Applications For Review Of The Tezacaftor/Ivacaftor Combination Treatment In People With Cystic Fibrosis By The FDA And EMA

Vertex Announces Acceptance Of Its Applications For Review Of The Tezacaftor/Ivacaftor Combination Treatment In People With Cystic Fibrosis By The FDA And EMA

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the acceptance of its applications for the use of the tezacaftor/ivacaftor combination treatment in people with cystic fibrosis (CF) ages 12 and...

Omeros Shares Lower After Completing Stock Offering, Juno Dips - Biotech Movers

Omeros Shares Lower After Completing Stock Offering, Juno Dips - Biotech Movers

The Seattle firm said Aug. 21 it completed an underwritten public offering of 3 million shares priced at $22.75 apiece.

10 High-Yielding Stocks to Own Ahead of a Surprising Late Summer Market Swoon

10 High-Yielding Stocks to Own Ahead of a Surprising Late Summer Market Swoon

Investors, antsy about increased volatility in the markets, might look to high dividend yielding REITs to ride out the uncertainty.

FDA Approves KALYDECO® (ivacaftor) For More Than 600 People Ages 2 And Older With Cystic Fibrosis Who Have Certain Residual Function Mutations

FDA Approves KALYDECO® (ivacaftor) For More Than 600 People Ages 2 And Older With Cystic Fibrosis Who Have Certain Residual Function Mutations

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.

Vertex Pharmaceuticals: Looking East, West and to the Quants

Vertex Pharmaceuticals: Looking East, West and to the Quants

Let's examine VRTX's sharp decline today.

Vertex Pharmaceuticals: Looking East, West and to the Quants

Vertex Pharmaceuticals: Looking East, West and to the Quants

Let's examine VRTX's sharp decline today.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BA, CAI, CNHI, FFWM, FSV, NEP, NOW, TGI, TRK, TSU, WPG Downgrades: AAT, BLMN, FBR, GSK, HZO, QDEL, VRTX Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Vertex Reports Second-Quarter 2017 Financial Results

Vertex Reports Second-Quarter 2017 Financial Results

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2017.

Another Day - Another Busy Slate of Earnings

Another Day - Another Busy Slate of Earnings

Ford Motor Co. leads a list of notable earnings reports being released throughout the day on Wednesday

Ford and the Fed - 5 Things You Must Know Before the Market Opens Wednesday

Ford and the Fed - 5 Things You Must Know Before the Market Opens Wednesday

U.S. stock futures are marginally higher on Wednesday ahead of an announcement from the Federal Reserve on interest rates.

Vertex And Concert Pharmaceuticals Complete Asset Purchase Agreement For CTP-656

Vertex And Concert Pharmaceuticals Complete Asset Purchase Agreement For CTP-656

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and Concert Pharmaceuticals, Inc.

U.S. Economy Is Probably Limping Along Because of Frustrating Consumers: Week Ahead

U.S. Economy Is Probably Limping Along Because of Frustrating Consumers: Week Ahead

Wall Street's first glimpse at the second quarter.

Closing Bell: Vertex Pharmaceuticals Up on String of Upgrades; Records for Wall Street

Closing Bell: Vertex Pharmaceuticals Up on String of Upgrades; Records for Wall Street

The Nasdaq and S&P 500 ended at records for the second day in a row.

S&P 500 and Nasdaq Hover at Session Highs, Apple on Pace for 9-Day Win Streak

S&P 500 and Nasdaq Hover at Session Highs, Apple on Pace for 9-Day Win Streak

S&P 500 and Nasdaq at record highs.

Vertex Growth Expected to Continue with Life-Changing Cystic Fibrosis Treatment

Vertex Growth Expected to Continue with Life-Changing Cystic Fibrosis Treatment

Remarkable data was released from Vertex's triple regiment combination trials.

TheStreet Quant Rating: A (Buy)